Shifting the Paradigm: The Case for Early Biologic Intervention in Psoriasis

Dermatologists are increasingly advocating for a shift from traditional, step-wise treatment models to an “elevator approach” for managing psoriasis. By initiating biologic therapies earlier in the disease course, clinicians may achieve superior skin clearance and reduce the long-term risk of systemic comorbidities. Evidence suggests that delaying advanced treatments until conventional therapies fail may result in missed opportunities for preventing disease progression and improving patient quality of life.

Why the “Step-Care” Model is Falling Out of Favor

Under this approach, patients typically begin with conventional systemic treatments or phototherapy. Biologic agents are often reserved as a last resort, utilized only after patients fail to respond to standard options. According to Chris Griffiths, MBBS, MD, an emeritus professor of dermatology at the University of Manchester, this process is “slow, laborious” and often results in patients failing to reach optimal disease control, ultimately losing valuable time during the early, most treatable stages of the condition.

The Clinical Evidence for Early Intervention

Research indicates that the timing of treatment significantly influences long-term outcomes. The phase 3b GUIDE study of guselkumab identified that patients who had been diagnosed for less than two years and had no prior exposure to biologics experienced the greatest success in achieving complete skin clearance. Similarly, the phase 3/4 STEPIn trial demonstrated that newly diagnosed patients treated with secukinumab achieved better skin clearance compared to those receiving ultraviolet B phototherapy.

Data from the British Association of Dermatologists Biologics Register (BADBIR) further supports this transition.

Impact on Comorbidities

Beyond skin health, early intervention may mitigate the systemic inflammatory risks associated with psoriasis. Research presented by Du Binh Phan, PhD, a research associate at the University of Manchester, suggests that starting biologics early can lead to a 50% reduction in the development of hepatic disease and a 40% reduction in the incidence of mental health disorders. While traditional models prioritize conventional drugs, these findings suggest that biologics offer a more robust protective effect against the cumulative, systemic impact of the disease.

How Community-Based Clinics Can Improve Access

A significant barrier to early intervention is the lack of access to specialized secondary care. In a pilot study conducted in Manchester, a multidisciplinary, community-based rapid access clinic was established to bridge this gap. During a seven-month period, the clinic provided expert care to 52 patients, 39 of whom met strict criteria for early-stage, untreated psoriasis.

Griffiths suggests that the future of psoriasis management lies in a “P4 medicine” model: predictive, preventive, personalized, and participatory. By utilizing a workforce of GPs, nurses, and pharmacists to initiate and monitor biologic therapies, dermatology services could become more accessible. In this model, consulting dermatologists would provide oversight through regular team meetings, allowing for high-quality care without the need for every patient to navigate the traditional, often congested, hospital-based referral system.

Frequently Asked Questions

• What is the “P4” medicine model? It is an approach to healthcare based on four pillars: predictive, preventive, personalized, and participatory.
• Why are biologics considered more effective for early treatment? Clinical data, such as the BADBIR findings, suggest that early use of biologics correlates with higher rates of complete skin clearance and a lower cumulative risk of comorbidities like depression and liver disease.
• Are there risks to starting biologics early? While biologics are highly effective, treatment decisions must be personalized. Clinicians consider individual patient health, including existing comorbidities like obesity, hypertension, and mental health status, when determining the best course of action.

Note: Chris Griffiths reports financial relationships with multiple organizations, including AbbVie, Almirall, Eli Lilly & Company, and Novartis. Du Binh Phan reported no relevant financial relationships.